What is Rocket Pharmaceuticals Inc (RCKT) stock price today?

Rocket Pharmaceuticals Inc (RCKT) currently trades at $3.48 per share. The stock has a market capitalization of $384.11M and a P/E ratio of —x.

Is RCKT stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Rocket Pharmaceuticals Inc has a Smart Value Score of 31/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is 0.46.

Is Rocket Pharmaceuticals Inc financially healthy?

Rocket Pharmaceuticals Inc's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of 0.46 places it in the distress.

RCKT

Rocket Pharmaceuticals Inc

NASDAQ: RCKT · HEALTHCARE · BIOTECHNOLOGY

$3.48

+0.00% today

Updated 2026-04-30

Market cap

$384.11M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.01

Dividend yield

—

52W range

$2 – $8

Volume

3.7M

Market cap

$384.11M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.01

Dividend yield

—

52W range

$2 – $8

Volume

3.7M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.5

Quality

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

0.5

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$8.75

+151.44%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy6 Buy6 Hold1 Sell1 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.08x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Altman Z 0.46 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-34.92M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-221.86M	$-245.59M	$-258.75M	$-223.12M	$-42.54M
EPS	—	—	—	—	$-2.01
Free cash flow	$-186.76M	$-211.39M	$-215.59M	$-190.45M	$-34.92M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
RCKT	$384.11M	31	4.3	3.0	5.0	6.5	—	Avoid
LLY	$789.69B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.64B	59	4.7	9.0	3.3	6.0	-41.97%	Buy
ABBV	$351.47B	63	4.0	8.0	4.7	5.0	-24.92%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Rocket Pharmaceuticals Inc trades at $3.48. Our Smart Value Score of 31/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 0.46, it sits in the distress.

Frequently asked questions

What is Rocket Pharmaceuticals Inc's stock price?

Rocket Pharmaceuticals Inc (RCKT) trades at $3.48.

Is Rocket Pharmaceuticals Inc overvalued?

Smart Value Score 31/100 (Grade F, Strong Sell).

What is the price target of Rocket Pharmaceuticals Inc (RCKT)?

The analyst target price is $8.75, representing +151.4% upside from the current price of $3.48.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

0.46 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.rocketpharma.com

Quick metrics

P/S ratio—

ROE-60.30%

Beta0.57

50D MA$4.10

200D MA$3.54

Shares out0.11B

Float0.09B

Short ratio—

Avg volume3.7M

Performance

1 week-9.97%

1 month-6.63%

3 months-5.38%

YTD+0.28%

1 year—

3 years—

5 years—

Compare

RCKT vs LLY →RCKT vs JNJ →RCKT vs ABBV →Stock screener →